MANCHESTER, NH--(Marketwired - December 10, 2013) -
Boston Therapeutics, Inc. (OTCQB: BTHE
) ("Boston Therapeutics" or "the Company"), an innovative developer of drugs that address diabetes using complex carbohydrate chemistry, has appointed Edward Shea as Vice President Business Development, Tina M. Gagnon as Consulting Director of Finance, and Yael T. Bobruff, Ph.D. as Clinical Affairs Manager, effective immediately.
David Platt, Ph.D., Chief Executive Officer, Boston Therapeutics, said, "As Boston Therapeutics enters the next phase of its growth, it is imperative that we attract top talent to help us advance and commercialize our drug development programs. Ed Shea and Tina Gagnon's business and finance backgrounds, and Dr. Bobruff's expertise in biology and research significantly strengthen our management team. I am pleased they have decided to join our Company and I look forward to working with them in the months and years ahead."
Mr. Shea brings 25 years of biopharmaceutical experience in commercial development, marketing and sales, having most recently served as Sr. Eastern Area Sales Director at ViroPharma, Inc. Mr. Shea's diverse experience includes more than 15 years of business development, marketing and sales leadership positions with GlaxoSmithKline and Salix Pharmaceuticals, as well as business development experience with two start up biopharmaceutical companies, ViroPharma and Critical Therapeutics. He holds a B.S. in Business/Marketing and an M.B.A. from Salve Regina University in Newport, RI.
Ms. Gagnon has more than 20 years of experience in finance. Most recently she served as Corporate Controller at Micronetics, Inc. (NASDAQ: NOIZ), where she oversaw a staff responsible for accounts receivable, accounts payable, inventory management and other activities. Prior to this, she was Controller at Amherst Technologies, LLC; Assistant Controller of Fruit of the Loom's Sports & Licensing Division; and Senior Corporate Auditor at Standex International Corp. She holds a B.S. in accountancy from Bentley College.
Dr. Bobruff was most recently a postdoctoral researcher in the Department of Systems Biology at Harvard University Medical School in Boston, where she studied the genetic processes and mechanisms contributing to the evolution of host-pathogen interactions. She earned a B.Sc. in biology from the Hebrew University of Jerusalem and a M.Sc. in civil and environmental engineering and a Ph.D. in biological science from Stanford University.
About Boston Therapeutics, Inc.
Boston Therapeutics, headquartered in Manchester, NH, (OTCQB: BTHE) is an innovator in designing drugs using complex carbohydrate chemistry. The Company's product pipeline is focused on developing and commercializing therapeutic molecules that address Type 2 diabetes, including: PAZ320, a non-systemic chewable therapeutic compound designed to reduce post-meal glucose elevation, and IPOXYN, an injectable anti-necrosis drug specifically designed to treat lower limb ischemia associated with diabetes. More information is available at www.bostonti.com.
Forward Looking Statements
This press release contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as "may," "estimate," "could," "expect" and others. They are based on our current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those described in the statements. Factors that could cause our actual performance to differ materially from those discussed in the forward-looking statements include, among others, that our plans, expectations and goals regarding the clinical trials are subject to factors beyond our control and provide no assurance of FDA approval of our drug development plans. Our clinical trials may not produce positive results in a timely fashion, if at all, and any necessary changes during the course of the trial could prove time consuming and costly. We may have difficulty in enrolling candidates for testing, which would affect our estimates regarding timing, and we may not be able to achieve the desired results. Any significant delays or unanticipated costs in the trials could delay obtaining meaningful results from Phase II and/or preparing for Phase III with the current cash on hand.
Upon receipt of FDA approval, we may face competition with other drugs and treatments that are currently approved or those that are currently in development, which could have an adverse effect on our ability to achieve revenues from this proposed indication. Plans regarding development, approval and marketing of any of our drugs, including PAZ320, are subject to change at any time based on the changing needs of our company as determined by management and regulatory agencies. To date, we have incurred operating losses since our inception, and our ability to successfully develop and market drugs may be affected by our ability to manage costs and finance our continuing operations. For a discussion of additional factors affecting our business, see our Annual Report on Form 10-K for the year ended December 31, 2012, and our subsequent filings with the SEC. You should not place undue reliance on forward-looking statements. Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking statements.